Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
147
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Impact of COVID-19 Vaccine and COVID-19 Infection on Vitiligo Activity and Progression

Xiaoyi ShiDepartment of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0009-0006-7943-796X
ORCID Icon,
Yifang SunDepartment of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of China
&
Xiaolan DingDepartment of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of ChinaCorrespondence[email protected]
Pages 3581-3587 | Received 08 Sep 2023, Accepted 09 Dec 2023, Published online: 15 Dec 2023

References

  • Wu T, Li J, Hu Y, Tang LV. Hematological questions in personalized management of COVID-19 vaccination. J Pers Med. 2023;13(2):259. doi:10.3390/jpm13020259
  • Abdul-Aziz Ahmed A, Jaber GN. Active vitiligo vulgaris following the administration of the Oxford–AstraZeneca (AZD1222) vaccine against SARS-CoV-2. Our Dermatol Online. 2022;13(2):219–220. doi:10.7241/ourd.20222.27
  • Kasmikha LC, Mansour M, Goodenow S, Kessler S, Appel J. Vitiligo following COVID-19 vaccination and primary infection: a case report and systematic review. Cureus. 2023;15(9):e45546. doi:10.7759/cureus.45546
  • Boniface K, Seneschal J, Picardo M, Taïeb A. Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clin Rev Allergy Immunol. 2018;54(1):52–67. doi:10.1007/s12016-017-8622-7
  • Tsai TF, Ng CY. COVID-19 vaccine-associated vitiligo: a cross-sectional study in a tertiary referral center and systematic review. J Dermatol. 2023;50(8):982–989. doi:10.1111/1346-8138.16799
  • Kaiqiao H, Bozhang L, Shuli L. Impact of a novel coronavirus infection epidemic on disease management in patients with vitiligo: a cross-sectional study. China J Lepr Skin Dis. 2023;39(04):231–235.
  • Okan G, Vural P. Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine. Dermatol Ther. 2022;35(3):e15280. doi:10.1111/dth.15280
  • Hou X, Wu N, Xu M, et al. Demographic and clinical feature disparity between progress and non-progress patients with vitiligo after COVID-19 vaccination: a cross-sectional study. Exp Dermatol. 2023. doi:10.1111/exd.14825
  • Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol. 2018;15(6):586–594. doi:10.1038/cmi.2017.151
  • Xu X, Zhang C, Jiang M, Xiang LF. Impact of treatment delays on vitiligo during the COVID-19 pandemic: a retrospective study. Dermatol Ther. 2021;34(4):e15014. doi:10.1111/dth.15014
  • Pastukhova E, Ghazawi FM. Eruptive halo nevi and new-onset vitiligo post-COVID-19 infection. JAAD Case Rep. 2023;34:43–44. doi:10.1016/j.jdcr.2023.01.030
  • Schmidt AF, Rubin A, Milgraum D, Wassef C. Vitiligo following COVID-19: a case report and review of pathophysiology. JAAD Case Rep. 2022;22:47–49. doi:10.1016/j.jdcr.2022.01.030

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.